459 reports of this reaction
4.1% of all ENTACAPONE reports
#2 most reported adverse reaction
HALLUCINATION is the #2 most commonly reported adverse reaction for ENTACAPONE, manufactured by Ajanta Pharma USA Inc.. There are 459 FDA adverse event reports linking ENTACAPONE to HALLUCINATION. This represents approximately 4.1% of all 11,238 adverse event reports for this drug.
Patients taking ENTACAPONE who experience hallucination should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HALLUCINATION is moderately reported among ENTACAPONE users, representing a notable but not dominant share of adverse events.
In addition to hallucination, the following adverse reactions have been reported for ENTACAPONE:
The following drugs have also been linked to hallucination in FDA adverse event reports:
HALLUCINATION has been reported as an adverse event in 459 FDA reports for ENTACAPONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HALLUCINATION accounts for approximately 4.1% of all adverse event reports for ENTACAPONE, making it one of the most commonly reported side effect.
If you experience hallucination while taking ENTACAPONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.